Drug Profile
Ivaltinostat - CrystalGenomics
Alternative Names: CG-200745; CG-745Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator CrystalGenomics
- Class Amides; Antineoplastics; Naphthalenes; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cancer
- Phase I/II Adenocarcinoma; Myelodysplastic syndromes; Pancreatic cancer
Most Recent Events
- 18 Jan 2024 Efficacy data from a phase I/II trial in adenocarcinoma presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 17 Nov 2023 CG Pharmaceuticals initiates phase II part of the phase Ib/II trial in Adenocarcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05249101)
- 15 Feb 2023 Machaon Biotherapeutics plans a phase I trial for Hematologic malignancy, Solid tumors and Fibrosis in Korea (NCT05716919)